Back when Illumina first announced they were going to acquire GRAIL, the general feeling in the M&A field was that this wouldn’t trigger any antitrust issues. I was asked if I could think of any difficulties. I didn’t claim back then that I was an antitrust expert (and still don’t), but I did wonder if...
Liquid biopsies represent one of the hottest trends in genomics and there has been an explosion of companies getting into this space. Naturally it’s been a topic of intense interest for consulting clients, so it’s an area that I monitor closely. There are well over 500 companies in the SanDiegOmics “Genome Technology” database, and currently...
The latest issue of GEN summarizes the VC activity in the biotech space for 2017 so far. There were 205 deals through the end of Q2 in which a total of $4.697B was raised. Three genomics companies alone accounted for $1.335B of that total: GRAIL = $900M (Q1) Guardant Health = $360M (Q2) WuXi NextCode...
Welcome to the SanDiegOmics blog! This is where I’ll be sharing with you the latest trends and updates in the genomics market, including next generation sequencing, genome editing, clinical interpretation, and more. I’ll also be commenting on genomics startup resources for San Diego, the epicenter of this rapidly growing industry. Finally, I’ll also be focusing...